

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK API 40699 Insp GMP 40699/7634946-0009

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : APTUIT (OXFORD) LIMITED

Site address : APTUIT (OXFORD) LIMITED, 110-111, 115 E-H, 117 AND 150 INNOVATION DRIVE, MILTON PARK, MILTON, ABINGDON, OX14 4RZ, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 23/01/2025 , it is considered that it complies with

- The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

-
- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
 - (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [1000021934] MAVORIXAFOR
- [1000010236] LENALIDOMIDE
- [1000015396] PLERIXAFOR
- [1000002302] FENFLURAMINE
- [2000006383] FROVATRIPTAN SUCCINATE

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

MAVORIXAFOR

- 3.1 Manufacture of Active Substance by Chemical Synthesis
 - 3.1.1 Manufacture Of Active Substance Intermediates
 - 3.1.2 Manufacture Of Crude Active Substance
 - 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
Salt release followed by crystallisation
- 3.5 General Finishing Steps
 - 3.5.1 Physical Processing Steps
Drying
 - 3.5.2 Primary Packaging
 - 3.5.3 Secondary Packaging
- 3.6 Quality Control Testing
 - 3.6.1 Physical / Chemical testing
 - 3.6.2 Microbiological testing (excluding sterility testing)

LENALIDOMIDE

- 3.1 Manufacture of Active Substance by Chemical Synthesis
 - 3.1.1 Manufacture Of Active Substance Intermediates
 - 3.1.2 Manufacture Of Crude Active Substance
 - 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
FINAL STEP INVOLVES CRYSTALLISATION
- 3.5 General Finishing Steps
 - 3.5.1 Physical Processing Steps
MANUFACTURE INVOLVES DRYING, MICRONISATION
 - 3.5.2 Primary Packaging
 - 3.5.3 Secondary Packaging
- 3.6 Quality Control Testing
 - 3.6.1 Physical / Chemical testing

PLERIXAFOR

- 3.6 Quality Control Testing
 - 3.6.1 Physical / Chemical testing

FENFLURAMINE

- 3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)

Chloride salt formation followed by purification by crystallisation.

3.5

General Finishing Steps

3.5.1 Physical Processing Steps

Drying

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6

Quality Control Testing

3.6.1 Physical / Chemical testing

FROVATRIPTAN SUCCINATE

3.1

Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)

Salt formation and crystallisation then drying

3.5

General Finishing Steps

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6

Quality Control Testing

3.6.1 Physical / Chemical testing

Restrictions or Remarks

This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. This certificate should be used in combination with the relevant authorisation/registration. A risk-based site inspection programme remains in force.

23/01/2025	Name and signature of the authorised person of the Competent Authority of United Kingdom
	Confidential
	Medicines and Healthcare products Regulatory Agency
	Tel : Confidential